Skip to Content

Cinqair Side Effects

Generic Name: reslizumab

Note: This document contains side effect information about reslizumab. Some of the dosage forms listed on this page may not apply to the brand name Cinqair.

For the Consumer

Applies to reslizumab: intravenous solution

Along with its needed effects, reslizumab (the active ingredient contained in Cinqair) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking reslizumab:

Rare

  • Cough
  • difficulty with swallowing
  • dizziness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fast heartbeat
  • hives, itching, or skin rash
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • redness of the skin
  • tightness in the chest
  • unusual tiredness or weakness

Some side effects of reslizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less Common

  • Throat pain

Incidence Not Known

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to reslizumab: intravenous solution

Gastrointestinal

Common (1% to 10%): Oropharyngeal pain[Ref]

Hematologic

Very common (10% or more): Elevated baseline creatine phosphokinase (CPK) (14%)[Ref]

Hypersensitivity

Uncommon (0.1% to 1%): Anaphylaxis[Ref]

Immunologic

Common (1% to 10%): Treatment emergent anti-reslizumab (the active ingredient contained in Cinqair) antibody response (low titer and often transient)[Ref]

Musculoskeletal

Very common (10% or more): Elevated baseline creatine phosphokinase (CPK) (14%)

Common (1% to 10%): Myalgia, chest pain, neck pain, muscle spasms, extremity pain, muscle fatigue, musculoskeletal pain[Ref]

Oncologic

Frequency not reported: Malignancy[Ref]

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. "Product Information. Cinqair (reslizumab)." Teva Pharmaceuticals USA, North Wales, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Hide